Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the GP Contract 2026/27, what cost benefit analysis his Department conducted in relation to the bonus GP practices in England will be paid to prescribe patients weight loss drugs.

The 2026/27 GP Contract introduces new incentives through the Quality and Outcomes Framework (QOF) for general practitioners to prescribe weight loss drugs.

At this stage, the Department has not made quantified estimates of net costs to the National Health Service over one-, five- or ten-year periods specifically attributable to these QOF indicators. The National Institute for Health and Care Excellence’s technology appraisal considered the clinical effectiveness and cost effectiveness of tirzepatide at a population level, and the QOF changes are intended to support appropriate implementation of that guidance.

QOF is an established lever for supporting the roll out of evidence-based care in general practice. Data gathered through QOF this year will be used to understand the impact of the new QOF obesity indicators on patient pathways and service use, and this evidence may inform future assessment of costs and benefits over time.